Search Results - "Viganò, M G"

Germline Polymorphisms in EGFR and Survival in Patients With Lung Cancer Receiving Gefitinib by Gregorc, V, Hidalgo, M, Spreafico, A, Cusatis, G, Ludovini, V, Ingersoll, RG, Marsh, S, Steinberg, SM, Viganò, MG, Ghio, D, Villa, E, Sparreboom, A, Baker, SD

“…The purpose of this study was to evaluate associations between germline epidermal growth factor receptor (EGFR) variants involved in transcriptional regulation…”
Get full text

The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy by Cinque, Chiara Pierotti, Maria Grazia Viganò, Arabella Bestetti, Caterina Fausti, Davide Bertelli, Adriano Lazzarin, Paola

“…The use of highly active anti-retroviral therapy in patients with HIV-related progressive multifocal leukoencephalopathy is associated with increased survival…”
Get full text

Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma by RENI, M, CEREDA, S, BONETTO, E, VIGANO, M. G, PASSONI, P, ZERBI, A, BALZANO, G, NICOLETTI, R, STAUDACHER, C, DI CARLO, V

“…PEFG regimen (cisplatin and epirubicin 40 mg/m2 day 1, gemcitabine 600 mg/m2 days 1 and 8, 5-fluorouracil (FU) 200 mg/m2/day continuous infusion) significantly…”
Get full text

Synthesis, structure-activity relationship and trypanocidal activity of pyrazole-imidazoline and new pyrazole-tetrahydropyrimidine hybrids as promising chemotherapeutic agents for Chagas disease by Monteiro, M.E., Lechuga, G., Lara, L.S., Souto, B.A., Viganó, M.G., Bourguignon, S.C., Calvet, C.M., Oliveira, F.O.R., Alves, C.R., Souza-Silva, F., Santos, M.S., Pereira, M.C.S.

“…Drug therapy for Chagas disease remains a major challenge as potential candidate drugs have failed clinical trials. Currently available drugs have limited…”
Get full text

The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma by FUMAGALLI, L, ZUCCHETTI, M, PARISI, I, VIGANO, M. G, ZECCA, B, CAREDDU, A, D'INCALCI, M, LAZZARIN, A

“…To investigate the pharmacokinetics of liposomal daunorubicin (DaunoXome) administered alone or in combination with antiviral therapy including protease…”
Get full text

Dose-Intense PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) in Advanced Pancreatic Adenocarcinoma: A Dose-Finding Study by Reni, M., Cereda, S., Bonetto, E., Viganò, M. G., Passoni, P., Zerbi, A., Balzano, G., Nicoletti, R., Staudacher, C., Di Carlo, V.

“…The aim of this study was to assess the maximum tolerated dose (MTD) of an intensified PEFG regimen administered every 14 days to patients with Stage III or…”
Get full text

Comparison between interleukin-2 and interleukin-12: effects on monocyte functions and their possible importance in the clinical significance of neopterin by Lissoni, P, Pittalis, S, Roselli, M G, Rovelli, F, Viganò, M G

Get more information

Patient-reported outcomes (PROs) and impact of lactate dehydrogenase (LDH) levels on outcomes in a phase 3 trial (NGR015) with best investigator choice (BIC) plus or minus NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM) by Gregorc, V., Bulotta, A., Viganò, M.G., Citterio, G., Petrella, G., Brioschi, E., Ducceschi, M., Gianni, L., Colombi, S., Rossoni, G., Salini, G., Savia, V., Lambiase, A., Bordignon, C.

Get full text

Combined treatment of non-small cell lung cancer with synchronous brain metastases: a single center experience by Melloni, G, Bandiera, A, Gregorc, V, Carretta, A, Ciriaco, P, Viganò, M, Franzin, A, Bolognesi, A, Picozzi, P, Zannini, P

“…The aim of this study was to analyze our experience with combined treatment of non-small cell lung cancer with synchronous brain metastases. Between 1992 and…”
Get full text

Relation between macrophage and T helper-2 lymphocyte functions in human neoplasms: neopterin, interleukin-10 and interleukin-6 blood levels in early or advanced solid tumors by Lissoni, P, Rovelli, F, Tisi, E, Brivio, F, Ardizzoia, A, Barni, S, Tancini, G, Saudelli, M, Cesana, E, Viganò, M G

“…At present, it is known that there are two main mechanisms responsible for cancer-related immunosuppression, mediated by macrophages and by TH2 lymphocytes…”
Get more information

Epstein-Barr virus DNA load in cerebrospinal fluid and plasma of patients with AIDS-related lymphoma by Bossolasco, Simona, Cinque, Paola, Ponzoni, Maurilio, Vigano, Maria Grazia, Lazzarin, Adriano, Linde, Annika, Falk, Kerstin I

“…Detection of Epstein-Barr virus (EBV) DNA in the cerebrospinal fluid (CSF) is associated with acquired immunodeficiency syndrome (AIDS)-related brain lymphoma…”
Get full text

Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM) by Gregorc, V., Ceresoli, G. L., Zucali, P. A., De Braud, F. G., Bajetta, E., Santoro, A., Viganò, M. G., Caligaris-Cappio, F., Lambiase, A., Bordignon, C.

“…Abstract only 7582 Background: NGR-hTNF is a VTA exploiting a tumor-homing peptide (NGR) that selectively binds to an aminopeptidase N (CD13) overexpressed on…”
Get full text

NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM): Preliminary results of multicenter phase II study by Gregorc, V., Zucali, P., Ceresoli, G. L., Noberasco, C., Bajetta, E., Santoro, A., Viganò, M. G., Caligaris-Cappio, F., Lambiase, A., Bordignon, C.

“…Abstract only…”
Get full text

Cetuximab (C) and gemcitabine (G) in elderly or adult PS2 advanced non small-cell lung cancer (NSCLC) patients (pts): The CALC1 randomised phase II trials by Gridelli, C., Mencoboni, M., Carrozza, F., Viganò, M. G., Gebbia, V., Verusio, C., Maione, P., Gallo, C., Perrone, F., Ciardiello, F.

“…Abstract only…”
Get full text

Detection of serum proteomic profile predictive for epidermal growth factor receptor tyrosine kinase inihibitors (EGFR-TKIs) in 1st line chemotherapy responders by Belli, C., Spreafico, A., Viganò, M. G., Lazzari, C., Roca, E., Villa, E., Roder, H., Grigorieva, J., Tsypin, M., Gregorc, V.

“…Abstract only…”
Get full text

Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patients by Lissoni, P, Barni, S, Ardizzoia, A, Scardino, E, Tancini, G, Viganò, M G

“…IL-6 levels have been proven to correlate with resistance to IL-2 immunotherapy. Since IL-6 may be produced by both macrophages and TH2 lymphocytes, it is not…”
Get more information

Targeted delivery of TNF using NGR-TNF in combination with chemotherapy as an effective and tolerable strategy in a hepatocarcinoma patient by Giovannini, M., Gregorc, V., Viganò, M. G., Roca, E., Lazzari, C., Spreafico, A., Belli, C., Citterio, G., Rossoni, G., Donadoni, G., Corti, A., Villa, E., Cappio, F. C.

“…Summary Targeted delivery of TNF to tumour vessels has been achieved by coupling this protein with the CNGRC peptide, an aminopeptidase N (CD13) ligand that…”
Get full text

Phase IV trial of dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma by Reni, M., Cereda, S., Passoni, P., Bonetto, E., Viganò, M. G., Balzano, G., Zerbi, A., Staudacher, C., Di Carlo, V.

“…Abstract only 4121 Background: In a phase III trial (Reni, Lancet Oncol 2005), PEFG regimen (cisplatin and epirubicin 40 mg/m 2 day 1, gemcitabine 600 mg/m 2…”
Get full text

Phase II trial of NGR-hTNF and doxorubicin in relapsed small cell lung cancer (SCLC) by Vigano', M. G., Cavina, R., Novello, S., Grossi, F., Santoro, A., Gregorc, V., Scagliotti, G., Garassino, I. M., Rossoni, G., Levra, M. G., Genova, C., Caligaris-Cappio, F., Lambiase, A., Bordignon, C.

“…Abstract only…”
Get full text

PHARMACOKINETIC STUDY OF THE LIPOSOMALEN CAPSULATED DAUNORUBICIN (DAUNOXOME) IN PATIENTS WITH HIV-ASSOCIATED KAPOSI'S SARCOMA by Fumagalli, L., Zucchetti, M., Parisi, I., Viganò, M. G., Brambilla, A. M., Zecca, B., D'Incalci, M., Lazzarin, A.

Get full text